LEXEO Therapeutics is a New York City-based, fully integrated biotechnology company currently headquartered at the Alexandria Center® for Life Science that aims to apply the transformational science of gene therapy to address some of the world’s most devastating genetic and acquired diseases. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine. 

Biotechnology

Education

LEXEO Therapeutics

R. Nolan Townsend

Julie Allen

Rand Monaghan

Emily H.

Amanda Wyatt Anderson

Jenny Speer

Leslie Dirisio

Jordan Dubow

Jenny Robertson

Richie Khanna

Ryan McHenry

Eric Adler

Keith Wonnacott

Ronald Crystal

Paul B. McCormac

The board of directors at LEXEO Therapeutics has a history of experience in the biotech industry, with a focus on cancer research. The current board chair is from cureteq AG, and has been an advisor and CEO at Esrum Biotech in the past. Other board members have experience from companies such as Abzu and DYSIS Medical. All board members have a background in biology from the University of Copenhagen.

Board of Directors

Leadership Team

CEO and Executive Team

Board of Directors

About

Team members

Other teams at LEXEO Therapeutics

Leadership Team

CEO and Executive Team